Noxopharm Ltd has released a press release.
March 2022 Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
- Orphan Drug Designation Granted to Noxopharm by US FDA
- First Patient Treated in CEP-2 Sarcoma Trial
- Appendix 4D and Half Year 2022 Financial Report
- December 2021 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- June 2022 Quarterly Activities Report and Appendix 4C
- Response to ASX Price Query
- Novel Dual-cell Therapy Results in Pancreatic Cancer
- September 2022 Quarterly Activities Report and Appendix 4C
- NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm